Ceritinib/Ceritinib (Zanda) belongs to which generation of targeted drugs and analysis of its clinical significance

Ceritinib (Ceritinib) is an oral tyrosine kinase inhibitor (TKI), which belongs to the second generation of ALK (anaplastic lymphoma kinase) targeted drugs. Compared with the first-generation ALK inhibitor crizotinib (Crizotinib), ceritinib has higher affinity and selectivity in inhibiting ALK mutations and drug-resistant mutations. It can also better penetrate the blood-brain barrier and has a significant effect on patients with central nervous system metastases.

Clinical studies have shown that ceritinib has excellent efficacy in patients with non-small cell lung cancer (NSCLC) who are resistant or intolerant to crizotinib. For ALK-positive patients who have previously received crizotinib and have disease progression, the objective response rate (ORR) of ceritinib can be achieved56%-62%, and the median progression-free survival (PFS) is about 6-8 months. This means that patients can achieve disease control, prolong survival time and improve quality of life after using ceritinib.

Compared with the first-generationALK inhibitors, an important clinical significance of ceritinib is its improved efficacy in patients with brain metastases. Due to its good blood-brain barrier penetration ability, ceritinib can effectively control brain metastases and reduce the risk of central nervous system recurrence, which is particularly critical for patients with advanced NSCLC. Research data shows that ceritinib can also achieve a local response rate of 30%-40% in patients with brain metastases and significantly improve the patients' neurological symptoms.

In addition, ceritinib’s advantages in resistance mechanisms make it an important choice for second-line or multi-line treatment. For patients who develop resistance after crizotinib treatment, ceritinib can re-inhibit the ALK signaling pathway, thereby prolonging disease remission. Overall, as a second-generation ALK inhibitor, ceritinib not only improves the treatment response rate of ALK-positive NSCLC patients, but also has important clinical value in brain metastasis control and drug resistance management, providing patients with a more comprehensive targeted treatment plan.

Reference materials:https://www.drugs.com/